Drug intelligence / Profile preview

CKDB-108

Development stage: Preclinical
Lead developer: CKD Bio
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

CKDB-108 is an antibiotic candidate currently in the research and development (R&D) stage, developed by the South Korean company CKD Bio. It is listed within the company's API (Active Pharmaceutical Ingredient) pipeline for the treatment of bacterial infections. As of the current reporting, specific details regarding its chemical structure, specific bacterial targets, or mechanism of action have not been publicly disclosed by the developer. The asset is part of a broader portfolio of antibiotic candidates being explored by CKD Bio, which leverages its expertise in fermentation and API production.

Beyond the preview

Go deeper on CKDB-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKDB-108.

Explore the full profile